Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE.
ACTOPLUS MET vs ROSIGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity by increasing glucose uptake and storage, reducing hepatic glucose production, and improving lipid metabolism.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
4-8 mg orally once daily or divided twice daily; maximum 8 mg/day.
None Documented
None Documented
Clinical Note
moderateRosiglitazone + Gatifloxacin
"Rosiglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateRosiglitazone + Rosoxacin
"Rosiglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateRosiglitazone + Levofloxacin
"Rosiglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateRosiglitazone + Trovafloxacin
"Rosiglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life is 3-4 hours. Clinically, this short half-life allows twice-daily dosing; steady-state is achieved within 2 days.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Primarily hepatic metabolism via CYP2C8; negligible renal excretion. Approximately 64% of dose excreted in urine (as metabolites) and 23% in feces over 96 hours. Less than 0.2% excreted unchanged in urine.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione